C1QTNF6 and neoplasm: One study employing a cRGD (cyclic arginine-glycine-aspartate)/RBCM (erythrocyte membrane) dual-headed nanocarrier platform co-delivering gemcitabine and silencing CTRP6 expression demonstrated that this strategy amplified ferroptosis in tumor cells via the NRF2/STAT3 signaling pathway [20].